BioTuesdays

Category - Markets

Neovasc Logo

Ladenburg cuts Neovasc to neutral; PT to 8 cents

Ladenburg Thalmann downgraded Neovasc (NASDAQ:NVCN) to “neutral” from “buy” and slashed its price target to 8 cents from $1, reflecting reduced revenue projections coupled with a greatly increased number of shares...

Corindus Logo

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

Vital Therapies Logo

WB ups Vital Therapies to OP and FVE to $35 from $10

William Blair upgraded Vital Therapies (NASDAQ:VTL) to “outperform” from “market perform” and raised its fair value estimate to $35 from $10 ahead of top-line data from a pivotal study expected in September. The stock...

ViewRay Logo

BTIG ups ViewRay PT to $14 from $10

BTIG raised its price target for ViewRay (NASDAQ:VRAY) to $14 from $10 after the stock pulled back from a recent climb to nearly $13. It closed at $11.05 on Aug. 3. “We felt the stock had overrun a bit to near $13 and...

Immune Pharmaceuticals

Maxim cuts Immune Pharma to hold; removes PT

Maxim Group downgraded Immune Pharmaceuticals (OTCQB:IMNP) to “hold” from “buy” and removed its prior price target of $2 as the company continues to resolve its financing overhang. The stock closed at 13 cents on Aug. 3...

Allena Pharmaceuticals Logo

Ladenburg starts Allena Pharma at buy; PT $23

Ladenburg Thalmann initiated coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $23 price target. The stock closed at $10.49 on August 1. Allena’s developmental program is focused on the reduction...

SELLAS Life Sciences Logo

HCW cuts SELLAS Life Sciences PT to $4 from $11

H.C. Wainwright slashed its price target for SELLAS Life Sciences (NASDAQ:SLS) to $4 from $11 after the company completed a $21.6-million offering of common shares, pre-funded warrants and warrants in July. The stock...

Tonix Pharmaceuticals Logo

Roth cuts Tonix Pharma to neutral; PT $1

Roth Capital Partners downgraded Tonix Pharmaceuticals (NASDAQ:TNXP) to “neutral” from “buy” with a price target of $1 after the company posted disappointing results from its interim Phase 3 analysis of Tonmya for the...

restorbio Logo

Leerink ups resTORbio PT to $45 from $35

Leerink raised its price target for resTORbio (NASDAQ:TORC) to $45 from $35 after the company announced positive top-line results from its Phase 2b clinical trial of RTB101. The stock finished at $13.47 on July 25. The...